vs
Side-by-side financial comparison of Cincinnati Financial (CINF) and Zoetis (ZTS). Click either name above to swap in a different company.
Cincinnati Financial is the larger business by last-quarter revenue ($2.8B vs $2.4B, roughly 1.2× Zoetis). Zoetis runs the higher net margin — 25.3% vs 9.6%, a 15.7% gap on every dollar of revenue. On growth, Zoetis posted the faster year-over-year revenue change (3.0% vs -1.7%). Over the past eight quarters, Cincinnati Financial's revenue compounded faster (5.2% CAGR vs 4.4%).
Cincinnati Financial Corporation offers property and casualty insurance, its main business, through The Cincinnati Insurance Company, The Cincinnati Indemnity Company and The Cincinnati Casualty Company. The company has 1.01% of the domestic property and casualty insurance premiums, which ranks it as the 20th largest insurance company by market share in the U.S.
Zoetis Inc. (/zō-EH-tis/) is an American drug company, the world's largest producer of medicine and vaccinations for pets and livestock. The company was a subsidiary of Pfizer, the world's largest drug maker, but with Pfizer's spinoff of its 83% interest in the firm it is now a completely independent company. The company directly markets its products in approximately 45 countries, and sells them in more than 100 countries. Operations outside the United States accounted for 50% of the total re...
CINF vs ZTS — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $2.8B | $2.4B |
| Net Profit | $274.0M | $603.0M |
| Gross Margin | — | 70.2% |
| Operating Margin | — | 31.9% |
| Net Margin | 9.6% | 25.3% |
| Revenue YoY | -1.7% | 3.0% |
| Net Profit YoY | 404.4% | 3.8% |
| EPS (diluted) | — | $1.37 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $2.8B | — | ||
| Q4 25 | $3.1B | $2.4B | ||
| Q3 25 | $3.7B | $2.4B | ||
| Q2 25 | $3.2B | $2.5B | ||
| Q1 25 | $2.6B | $2.2B | ||
| Q4 24 | $2.5B | $2.3B | ||
| Q3 24 | $3.3B | $2.4B | ||
| Q2 24 | $2.5B | $2.4B |
| Q1 26 | $274.0M | — | ||
| Q4 25 | $676.0M | $603.0M | ||
| Q3 25 | $1.1B | $721.0M | ||
| Q2 25 | $685.0M | $718.0M | ||
| Q1 25 | $-90.0M | $631.0M | ||
| Q4 24 | $405.0M | $581.0M | ||
| Q3 24 | $820.0M | $682.0M | ||
| Q2 24 | $312.0M | $624.0M |
| Q1 26 | — | — | ||
| Q4 25 | — | 70.2% | ||
| Q3 25 | — | 71.5% | ||
| Q2 25 | — | 73.6% | ||
| Q1 25 | — | 72.0% | ||
| Q4 24 | — | 69.5% | ||
| Q3 24 | — | 70.6% | ||
| Q2 24 | — | 71.7% |
| Q1 26 | — | — | ||
| Q4 25 | 27.2% | 31.9% | ||
| Q3 25 | 37.9% | 37.0% | ||
| Q2 25 | 26.3% | 36.7% | ||
| Q1 25 | -5.0% | 36.5% | ||
| Q4 24 | 18.9% | 31.6% | ||
| Q3 24 | 31.3% | 36.6% | ||
| Q2 24 | 15.2% | 33.0% |
| Q1 26 | 9.6% | — | ||
| Q4 25 | 21.9% | 25.3% | ||
| Q3 25 | 30.1% | 30.0% | ||
| Q2 25 | 21.1% | 29.2% | ||
| Q1 25 | -3.5% | 28.4% | ||
| Q4 24 | 16.0% | 25.1% | ||
| Q3 24 | 24.7% | 28.6% | ||
| Q2 24 | 12.3% | 26.4% |
| Q1 26 | — | — | ||
| Q4 25 | $4.29 | $1.37 | ||
| Q3 25 | $7.11 | $1.63 | ||
| Q2 25 | $4.34 | $1.61 | ||
| Q1 25 | $-0.57 | $1.41 | ||
| Q4 24 | $2.57 | $1.29 | ||
| Q3 24 | $5.20 | $1.50 | ||
| Q2 24 | $1.98 | $1.37 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $1.2B | — |
| Total DebtLower is stronger | $816.0M | — |
| Stockholders' EquityBook value | $15.7B | $3.3B |
| Total Assets | $41.2B | $15.5B |
| Debt / EquityLower = less leverage | 0.05× | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $1.2B | — | ||
| Q4 25 | $148.0M | — | ||
| Q3 25 | $1.6B | $2.1B | ||
| Q2 25 | $1.1B | $1.4B | ||
| Q1 25 | $1.1B | $1.7B | ||
| Q4 24 | $1.3B | $2.0B | ||
| Q3 24 | $1.8B | $1.7B | ||
| Q2 24 | $771.0M | $1.6B |
| Q1 26 | $816.0M | — | ||
| Q4 25 | $861.0M | — | ||
| Q3 25 | $858.0M | — | ||
| Q2 25 | $859.0M | — | ||
| Q1 25 | $853.0M | — | ||
| Q4 24 | $850.0M | — | ||
| Q3 24 | $849.0M | — | ||
| Q2 24 | $849.0M | — |
| Q1 26 | $15.7B | — | ||
| Q4 25 | $15.9B | $3.3B | ||
| Q3 25 | $15.4B | $5.4B | ||
| Q2 25 | $14.3B | $5.0B | ||
| Q1 25 | $13.7B | $4.7B | ||
| Q4 24 | $13.9B | $4.8B | ||
| Q3 24 | $13.8B | $5.2B | ||
| Q2 24 | $12.8B | $5.0B |
| Q1 26 | $41.2B | — | ||
| Q4 25 | $41.0B | $15.5B | ||
| Q3 25 | $40.6B | $15.2B | ||
| Q2 25 | $38.8B | $14.5B | ||
| Q1 25 | $37.3B | $14.1B | ||
| Q4 24 | $36.5B | $14.2B | ||
| Q3 24 | $37.0B | $14.4B | ||
| Q2 24 | $34.8B | $14.2B |
| Q1 26 | 0.05× | — | ||
| Q4 25 | 0.05× | — | ||
| Q3 25 | 0.06× | — | ||
| Q2 25 | 0.06× | — | ||
| Q1 25 | 0.06× | — | ||
| Q4 24 | 0.06× | — | ||
| Q3 24 | 0.06× | — | ||
| Q2 24 | 0.07× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $893.0M |
| Free Cash FlowOCF − Capex | — | $732.0M |
| FCF MarginFCF / Revenue | — | 30.7% |
| Capex IntensityCapex / Revenue | — | 6.7% |
| Cash ConversionOCF / Net Profit | — | 1.48× |
| TTM Free Cash FlowTrailing 4 quarters | — | $2.3B |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $947.0M | $893.0M | ||
| Q3 25 | $1.1B | $938.0M | ||
| Q2 25 | $741.0M | $486.0M | ||
| Q1 25 | $310.0M | $587.0M | ||
| Q4 24 | $642.0M | $905.0M | ||
| Q3 24 | $912.0M | $951.0M | ||
| Q2 24 | $742.0M | $502.0M |
| Q1 26 | — | — | ||
| Q4 25 | $939.0M | $732.0M | ||
| Q3 25 | $1.1B | $805.0M | ||
| Q2 25 | $737.0M | $308.0M | ||
| Q1 25 | $307.0M | $438.0M | ||
| Q4 24 | $638.0M | $689.0M | ||
| Q3 24 | $906.0M | $784.0M | ||
| Q2 24 | $737.0M | $370.0M |
| Q1 26 | — | — | ||
| Q4 25 | 30.4% | 30.7% | ||
| Q3 25 | 29.8% | 33.5% | ||
| Q2 25 | 22.7% | 12.5% | ||
| Q1 25 | 12.0% | 19.7% | ||
| Q4 24 | 25.1% | 29.7% | ||
| Q3 24 | 27.3% | 32.8% | ||
| Q2 24 | 29.0% | 15.7% |
| Q1 26 | — | — | ||
| Q4 25 | 0.3% | 6.7% | ||
| Q3 25 | 0.1% | 5.5% | ||
| Q2 25 | 0.1% | 7.2% | ||
| Q1 25 | 0.1% | 6.7% | ||
| Q4 24 | 0.2% | 9.3% | ||
| Q3 24 | 0.2% | 7.0% | ||
| Q2 24 | 0.2% | 5.6% |
| Q1 26 | — | — | ||
| Q4 25 | 1.40× | 1.48× | ||
| Q3 25 | 0.99× | 1.30× | ||
| Q2 25 | 1.08× | 0.68× | ||
| Q1 25 | — | 0.93× | ||
| Q4 24 | 1.59× | 1.56× | ||
| Q3 24 | 1.11× | 1.39× | ||
| Q2 24 | 2.38× | 0.80× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CINF
| Property casualty | $2.6B | 93% |
| Life | $105.0M | 4% |
| Other | $92.0M | 3% |
| Fee revenues | $1.0M | 0% |
ZTS
| Other | $1.3B | 56% |
| Livestock | $234.0M | 10% |
| Pain Sedation | $209.0M | 9% |
| Other Pharmaceuticals | $188.0M | 8% |
| Swine | $125.0M | 5% |
| Poultry | $117.0M | 5% |
| Fish | $81.0M | 3% |
| Other Non Pharmaceuticals | $70.0M | 3% |
| Manufactured Product Other | $18.0M | 1% |
| Medicated Feed Additives | $12.0M | 1% |
